Moreover, in the DAPHNE trial, patients with stage II-III HER2+ breast cancer were treated with neoadjuvant paclitaxel plus double anti-HER2 blockade with trastuzumab and pertuzumab, obtaining a pCR rate of 56.7% and excellent long-term outcomes without further adjuvant chemotherapy in case of pCR achievement [21]. This evidence concerns the gene ERBB2 and breast carcinoma.